Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Medtronic
Argus Health
US Army
Farmers Insurance
Fish and Richardson
Dow
Daiichi Sankyo

Generated: June 25, 2018

DrugPatentWatch Database Preview

INCIVEK Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Summary for INCIVEK
International Patents:124
US Patents:3
Applicants:1
NDAs:1
Bulk Api Vendors: 56
Clinical Trials: 11
Patent Applications: 136
Formulation / Manufacturing:see details
DailyMed Link:INCIVEK at DailyMed
Drug patent expirations by year for INCIVEK
Synonyms for INCIVEK
(1S,3aR,6aS)-(2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta(c)pyrrole-1-carboxamide
(1S,3aR,6aS)-(2S)-2-Cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta[c]pyrrole-1-carboxamide
(1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxo-hexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide
(1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide
(1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cydopropylamino)-1,2-dioxo-hexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide
(1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-3-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide
(1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-6-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide
(1S,3aR,6aS)-2-[(2S)-2-({(2S)-2-cyclohexyl-2-[(pyrazin-2-ylcarbonyl)amino]acetyl}amino)-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]octahydrocyclopenta[c]pyrrole-1-carboxamide
(1S,3aR,6aS)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-1-carboxamide
(3S,3aS,6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethyl-butanoyl]-N-[(1S)-1-[2-(cyclopropylamino)-2-oxo-acetyl]butyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide
(3S,3aS,6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide
(3S)-3-{[(1S,3aR,6aS)-2-[(2S)-2-[(2S)-2-cyclohexyl-2-(pyrazin-2-ylformamido)acetamido]-3,3-dimethylbutanoyl]-octahydrocyclopenta[c]pyrrol-1-yl]formamido}-N-cyclopropyl-2-oxohexanamide
2-(2-{2-Cyclohexyl-2-[(pyrazine-2-carbonyl)-amino]-acetylamino}-3,3-dimethyl-butyryl)-octahydro-cyclopenta[c]pyrrole-1-carboxylic acid (1-cyclopropylaminooxalyl-butyl)-amide
402957-28-2
569364-34-7
655M5O3W0U
957T282
A18739
AB0027979
ABP000273
AC1MHSY4
AIDS-213006
AIDS213006
AK128854
AKOS005145815
AN-3508
AOB87136
AS-16995
BBAWEDCPNXPBQM-GDEBMMAJSA-N
BDBM50326056
C36H53N7O6
cc-71
CHEBI:68595
CHEMBL231813
CS-0285
D07ZAH
D09012
D0X9CH
DB05521
DTXSID40193304
EX-A006
FD7166
GTPL7871
HSDB 8125
HY-10235
Incivek (TN)
Incivek(TM)
Incivo
Incivo (TN)
LY 570310
LY-570310
MFCD11616089
MolPort-006-170-103
MP 424
MP-424
PubChem22395
Q-101417
Q-4436
S-Telaprevir
s1538
SC-28369
SCHEMBL183996
ST1151107
Telaprevir
Telaprevir (JAN/USAN/INN)
Telaprevir (VX-950)
Telaprevir (VX950)
Telaprevir [USAN:INN]
Telaprevir,VX-950
Telaprevir; VX-950
Telaprevir(VX-950)
Telavic
UNII-655M5O3W0U
VRT 111950
VRT-111950
VRT111950
VX 950
VX-950
VX-950(Telaprevir)
W9903
WO-00218369
ZINC3992480

US Patents and Regulatory Information for INCIVEK

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vertex Pharms INCIVEK telaprevir TABLET;ORAL 201917-001 May 23, 2011 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Vertex Pharms INCIVEK telaprevir TABLET;ORAL 201917-001 May 23, 2011 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Vertex Pharms INCIVEK telaprevir TABLET;ORAL 201917-001 May 23, 2011 DISCN No No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Premature patent expiration for: INCIVEK

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
➤ Sign Up INCIVEK ➤ Sign Up
➤ Sign Up INCIVEK ➤ Sign Up

Non-Orange Book US Patents for INCIVEK

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,252,923 Peptidomimetic protease inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for INCIVEK

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB12/010 United Kingdom ➤ Sign Up PRODUCT NAME: TELAPREVIR OR PHARMACEUTICALLY ACCEPTABLE SALTS AND/OR SOLVATES OF TELAPREVIR OR SOLVATES OF SUCH SALTS.; REGISTERED: UK EU/1/11/720/001 20110919
1320540/01 Switzerland ➤ Sign Up FORMER OWNER: VERTEX PHARMACEUTICALS INCORPORATED, US
C0018 France ➤ Sign Up PRODUCT NAME: TELAPREVIR ET LES SELS ET/OU LES SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES DU TELAPREVIR OU LES SOLVATES DE TELS SELS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
0 Finland ➤ Sign Up
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Chubb
Julphar
Citi
Cerilliant
Baxter
US Department of Justice
Express Scripts
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.